Close
close
September 29th, 2006

Octapharma to Participate in the Upcoming ESID Congress in Budapest from October 4 – 7, 2006


The forthcoming ESID in Budapest is a joint meeting of the European Society of Immunodeficiency (ESID), International Patient Organisation for Immunodeficiency (IPOPI) and the International Nursing Group for Immunodeficiency (INGID).

Some time ago an East-European physician education program was launched under the name of the “J Project”. The aim of the J Project is to increase professional and social awareness of primary immunodeficiency diseases in 10 East-European countries with a population exceeding 150 million.

This project and the congress provide a good platform for researchers and clinicians to get together and discuss the developments and understanding of treating PID. Octapharma is a partner in sponsoring the ESID/IPOPI/INGID congress held in Budapest .

Octapharma will participate at the exhibition with a 45sqm booth in the Great Hall, Diamond Sector (Booth No. 1).  Delegates attending the congress are invited to visit us in the exhibition for refreshments. One of the attractions on offer will be the chance to take part in an exciting quiz on our two products, Octagam and Gammanorm, with the opportunity of winning grand prizes. Our two products provide PID treaters with a choice of IgG administration depending on specific patients needs or preferences. An instructional video for subcutaneous Ig home treatment will be on display and distributed to delegates from the booth.

Further to this, Octapharma is actively involved in researching PID and some of the results will be included in two posters during the congress. Please visit our booth to learn more about our company, our products and the following scientific presentations:

Poster Publications
Capacity of prion protein removal during manufacturing of IgG concentrates

A. Neisser-Svae, A. Buchacher, G. Iberer, L. Biesert, T. Schmidt, J. Römisch, T.E. Svae

Comparison of the viscorsity of three subcutaneous immunoglobuin brands (SCIG) – Potential implications for clinical use

Stefan Haag, Andrea Buchacher, Günger Iberer

In addition to the poster publications listed above, the following handouts will be available at our booth:

Scientific Handouts
Capacity of prion protein removal during manufacturing of IgG concentrates

Comparison of the viscorsity of three subcutaneous immunoglobuin brands (SCIG) – Potential implications for clinical use
Biochemical comparison of three different subcutaneous immunoglobulins – Gammanorm and two competitor products 
Primary Immune Deficiency (PID): Feasibility of home therapy with Octagam in France

Pharmacokinetic  properties of Octagam in  paediatric patients with PID or HIV infection 

We will also have the two products brochures for Octagam and Gammanorm available at our booth as well as data from the 11-year pharmacovigilance study “Octagam in Children and Adolescents with Primary Immunodeficiency Disorders”.

We look forward to seeing you in Budapest !





© Octapharma AG, 2006